NCT04662684View on ClinicalTrials.gov

Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

July 10, 2021

Study Completion Date

August 30, 2021

Conditions
Covid19Venous Thromboembolism
Interventions
DRUG

Rivaroxaban 10 MG

No intervention

Trial Locations (1)

09030370

Science Valley Research Institute, Santo André

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Science Valley Research Institute

OTHER